<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04269603</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0661</org_study_id>
    <nct_id>NCT04269603</nct_id>
  </id_info>
  <brief_title>LTA Assessement Using Aggregometer TA-8V (Stago®)</brief_title>
  <acronym>NORMAGREG</acronym>
  <official_title>Normal Values and Quality Assessment of Light Transmission Aggregometry (LTA) Using Aggregometer TA-8V (Stago®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploring platelet functions requires aggregation tests platelet. The Haematology Laboratory
      of Hospices Civils de Lyon currently has two new TA-8V plate aggregation automatons® (Stago).

      The supplier of these devices does not offer reference values for these tests. There are also
      no references in the data literature. Therefore reference values must be established from
      healthy volunteer subjects.

      The use of these automatons is subject to the NF (French Standard) EN (European Standard) ISO
      (International Organization for Standardization) 15189 standard of the COFRAC ( French
      Accreditation Comity) that requires checking their proper functioning. This audit must be
      traced in a method validation folder.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelets aggregation results for LTA on TA-8V (Stago®)</measure>
    <time_frame>Month 0</time_frame>
    <description>Normal values for platelets aggregation will be established using various agonists to activate platelets. :
• Ristocetin (STAGO®)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelets aggregation results for LTA on TA-8V (Stago®)</measure>
    <time_frame>Month 3</time_frame>
    <description>Normal values for platelets aggregation will be established using various agonists to activate platelets. :
Collagen (STAGO®)
ADP (adenosine diphosphate) (STAGO®)
Arachidonate (STAGO®)
TRAP (Thrombin Receptor Activating Platelet) (STAGO®)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelets aggregation results for LTA on TA-8V (Stago®)</measure>
    <time_frame>Month 6</time_frame>
    <description>Normal values for platelets aggregation will be established using various agonists to activate platelets. :
Epinephrine (STAGO®)
PMA (phorbol 12-myristate 13 acetate) (SIGMA®)
PAF (Platelet Activator Factor) (BACHEM®)
Ionophore calcium (SIGMA®)
11-Epoxy (SIGMA®)
Prostaglandin E1 (SIGMA®)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LTA intra assay variability</measure>
    <time_frame>Month 0</time_frame>
    <description>Intra assay variability of maximal platelet aggregation will be assessed by calculating a coefficient of variation of the studied parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTA intra assay variability</measure>
    <time_frame>Month 3</time_frame>
    <description>Intra assay variability of maximal platelet aggregation will be assessed by calculating a coefficient of variation of the studied parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTA intra assay variability</measure>
    <time_frame>Month 6</time_frame>
    <description>Intra assay variability of maximal platelet aggregation will be assessed by calculating a coefficient of variation of the studied parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTA inter operator variability</measure>
    <time_frame>Month 0</time_frame>
    <description>Inter operator variability of maximal platelet aggregation will be assessed by percentage of agreement (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTA inter operator variability</measure>
    <time_frame>Month 3</time_frame>
    <description>Inter operator variability of maximal platelet aggregation will be assessed by percentage of agreement (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTA inter operator variability</measure>
    <time_frame>Month 6</time_frame>
    <description>Inter operator variability of maximal platelet aggregation will be assessed by percentage of agreement (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Agonist reagents stability duration</measure>
    <time_frame>up to 2 months post reagents reconstitution and 2 months post reconstitution with the same technician, the same automaton and the same healthy volunteer sample.</time_frame>
    <description>Reagents will be reconstituted and stored at -20°C. They will be used for aggregation assay extemporaneously, 1 week, 2 weeks , 1 month and 2 months post reconstitution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Agonist reagents stability duration</measure>
    <time_frame>up to 2 months post reagents reconstitution</time_frame>
    <description>Reagents will be reconstituted and stored at -20°C. They will be used for aggregation assay extemporaneously, 1 week, 2 weeks , 1 month and 2 months post reconstitution.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>30 healthy adult volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy adult volunteers without hemorrhagic diathesis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Take blood (TA-8V (Stago®)</intervention_name>
    <description>Healthy volunteers will have 3 blood samples at M0, M3 and M6.</description>
    <arm_group_label>30 healthy adult volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults aged between 18 and 70 years

          -  Weighting more than 50 kg

          -  Subjects having signed informed consent

          -  Subjects registered in the French health-care system database

        Exclusion Criteria:

          -  Personal history of anemia, thrombopenia, hemorrhagic disease

          -  Caffeine intake 2 hours prior to blood sampling

          -  Tobacco intake in the half hour prior to blood sampling

          -  Use of any drug impacting platelet function

          -  for antiplatelet agents: at least 10 days prior to blood sampling

          -  for anti-depressants: at least 10 days prior to blood sampling

          -  for non-steroid anti-inflammatories: at least 3 days prior to blood sampling

          -  Refusal to undergo the 3 visits and 3 blood samples of the study

          -  Refusal to sign the informed consent form

          -  No registration in the French Health-care system database

          -  Pregnant women and women who are breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sandra LE QUELLEC, MD, PhD</last_name>
    <phone>4 72 12 96 30</phone>
    <phone_ext>+33</phone_ext>
    <email>sandra.le-quellec@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy DERICQUEBOURG, Pharm.D</last_name>
    <phone>4 72 12 96 52</phone>
    <phone_ext>+33</phone_ext>
    <email>amy.dericquebourg@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Haemostasis Unit/Haematology Laboratory, Groupement Hospitalier Est</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra LE QUELLE, MD</last_name>
      <phone>4 72 12 96 30</phone>
      <phone_ext>+33</phone_ext>
      <email>sandra.le-quellec@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Amy DERICQUEBOURG, Pharm.D</last_name>
      <phone>4 72 12 96 52</phone>
      <phone_ext>+33</phone_ext>
      <email>amy.dericquebourg@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sandra LE QUELLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>light transmission aggregometry</keyword>
  <keyword>platelets</keyword>
  <keyword>platelet functions</keyword>
  <keyword>von Willebrand disease</keyword>
  <keyword>quality assessment</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

